A new study looking at the way human cells activate the immune system in response to SARS-CoV-2 infection could open the door to even more effective and powerful vaccines against the coronavirus and its rapidly emerging variants.
Brazilian researchers show that a combination of inflammatory cytokines in the blood and cannabis use, daily or during adolescence, heightens the odds of developing psychiatric disorders.
Researchers from the University of Kent's School of Psychology have found that when people are presented with the idea of a COVID-19 'immunity passport,' they show less willingness to follow social distancing and face covering guidelines.
Research published in the journal ACS Materials and Interfaces has provided new understanding of how false-negative results in Lateral Flow Tests occur and provides opportunity for simple improvements to be made.
A Clemson University researcher has developed a protein which links natural killer cells in the human body's immune system to breast cancer cells. It's a novel approach to developing breast cancer-specific immunotherapy and could lead to new treatment options for the world's most common cancer.
Immune cells that normally repair tissues in the body can be fooled by tumors when cancer starts forming in the lungs and instead help the tumor become invasive, according to a surprising discovery reported by Mount Sinai scientists in Nature in June.
New research published in BMJ Open shows that community pharmacy could play a 'key clinical role' in the future of COVID-19 vaccination programmes, according to a study led by Aston University in Birmingham, UK, in collaboration with UK and international researchers.
What The Study Did:Â This study demonstrated an association between receiving the mRNA-1273 (Moderna) vaccine and a reduction in SARS-CoV-2 infection in health care workers beginning eight days after the first dose.
Evaluation of three COVID-19 vaccine candidates in 2020-21 during a worldwide pandemic was unprecedented in terms of urgency and scope. Responsibility for the safety, integrity and scientific validity of U.S. trials fell to 12 experts of the federally appointed COVID-19 Vaccine Data and Safety Monitoring Board, who in turn report to an oversight group. This team has now taken the unusual step of publishing details of their review process in The Journal of Infectious Diseases.
A review of more than 9,000 US patients with severe COVID-19 infection showed less than 1% contracted the illness again, with an average reinfection time of 3.5 months after an initial positive test. Those are the findings from a study conducted by researchers from the University of Missouri School of Medicine and MU Health Care.